Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition
9 May 2026 – 14 May 2026 · Cape Town, South Africa
461-04-011 ISMRM Abstract

Impact of Response Evaluation Criteria on DCE-MRI Radiomics in Predicting Neoadjuvant Chemotherapy Response in Breast Cancer

Accepted
Weipeng Zhang 1, Xiang Li1, Mengzhou Sun2, Xiaoyun Liang3
1Department of Radiology, The Second Affiliated Hospital of Dalian Medical University, Dalian, China
2Institute of Research and Clinical Innovations, Neusoft Medical Systems Co. Ltd, Beijing, China
3Institute of Research and Clinical Innovations, Neusoft Medical Systems Co., Ltd, Shanghai, China
Presenting Author: Weipeng Zhang

Synopsis

Motivation:
Goals:
Approach:
Results:
Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

Log in

References

1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263. doi:10.3322/caac.21834 [doi]
2. Gradishar WJ, Moran MS, Abraham J, et al. Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024;22(5):331-357. doi:10.6004/jnccn.2024.0035 [doi]
3. Chen, Z., Huang, M., Lyu, J., Qi, X., He, F., & Li, X. (2023). Machine learning for predicting breast-conserving surgery candidates after neoadjuvant chemotherapy based on DCE-MRI. Frontiers in Oncology, 13, 1174843. DOI: 10.3389/fonc.2023.1174843 [doi]
4. Xiong, Q., Zhou, X., Liu, Z., Lei, C., Yang, C., Yang, M., ... & Wang, K. (2020). Multiparametric MRI-based radiomics analysis for prediction of breast cancers insensitive to neoadjuvant chemotherapy. Clinical and Translational Oncology, 22(1), 50-59.DOI: 10.1007/s12094-019-02109-8 [doi]

Cite this abstract